Frequency of CAEs in ponatinib-treated patients
| New-onset CAE . | Cumulative incidence, n (%) (n = 78)* . | Ponatinib 45 mg/d, n (%) . | Ponatinib 30 mg/d, n (%) . | Ponatinib 15 mg/d, n (%) . |
|---|---|---|---|---|
| Arrhythmia | 7 (9.0) | 1 (1.3) | 3 (3.8) | 3 (3.8) |
| Hypertension | 6 (7.7) | 3 (3.8) | 2 (2.6) | 1 (1.3) |
| Venous thrombosis | 4 (5.1) | 1 (1.3) | 3 (3.8) | 0 (0.0) |
| Heart failure | 4 (5.1) | 1 (1.3) | 2 (2.6) | 1 (1.3) |
| Myocardial infarction | 3 (3.8) | 0 (0.0) | 1 (1.3) | 2 (2.6) |
| Arterial thrombosis† | 1 (1.3) | 0 (0.0) | 1 (1.3) | 0 (0.0) |
| Peripheral arterial disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cerebrovascular accident | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| New-onset CAE . | Cumulative incidence, n (%) (n = 78)* . | Ponatinib 45 mg/d, n (%) . | Ponatinib 30 mg/d, n (%) . | Ponatinib 15 mg/d, n (%) . |
|---|---|---|---|---|
| Arrhythmia | 7 (9.0) | 1 (1.3) | 3 (3.8) | 3 (3.8) |
| Hypertension | 6 (7.7) | 3 (3.8) | 2 (2.6) | 1 (1.3) |
| Venous thrombosis | 4 (5.1) | 1 (1.3) | 3 (3.8) | 0 (0.0) |
| Heart failure | 4 (5.1) | 1 (1.3) | 2 (2.6) | 1 (1.3) |
| Myocardial infarction | 3 (3.8) | 0 (0.0) | 1 (1.3) | 2 (2.6) |
| Arterial thrombosis† | 1 (1.3) | 0 (0.0) | 1 (1.3) | 0 (0.0) |
| Peripheral arterial disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cerebrovascular accident | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |